| 标题 |
 Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study |
| 网址 | |
| DOI | |
| 其它 | Kudo M, Abou-Alfa GK, et al. EMERALD-3 Investigators. Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study. Lancet Oncol. 2026 Sep;27(9):1077-1093. |
| 求助人 | |
| 下载 | 求助已完成，仅限求助人下载。 |
PDF的下载单位、IP信息已删除
(2025-6-4)
DW
无极微光
秋风
xing_xing
Nole
aaaa
cdercder
李杰杰
Criminology34
学术文献互助
Enigma_GEB
昏睡的蟠桃
修仙中
Lo
我能私信骂你吗
舒服的楷瑞
科研狗
刘泽楷
the_coco
DOC_XIONG
皖公网安备34019202002308
